CD135 - PDFSEARCH.IO - Document Search Engine

CD135
Results: 32

#	Item
21	CANCER GENETICS REQUISITION Cancer Genetics Lab Room # 3305 British Columbia Cancer Agency 600 West 10th Avenue, Vancouver BC V5Z 4E6 Phone: ([removed]Ext[removed]Reports) Ext[removed]Cytogenetics) Ext[removed]Molecular Add to Reading List Source URL: www.bccancer.bc.ca Language: English - Date: 2014-03-22 18:25:56 Genetics Evolutionary biology Mutation Cancer CD135 Multiple endocrine neoplasia type 2 Biology Health Medicine
22	Automated Data Analysis in NMR Fragment Based Screening by ACD/Automation Server Add to Reading List Source URL: www.acdlabs.com Language: English - Date: 2012-05-01 07:16:17 Drug discovery Clinical research Tyrosine kinase receptors Plexxikon Protein kinase Fragment-based lead discovery AKT CD135 Tyrosine kinase Pharmaceutical sciences Pharmacology Medicinal chemistry
23	Molecular methods to detect MRD in AML David Grimwade Dept. of Medical & Molecular Genetics, King’s College London School of Medicine Add to Reading List Source URL: www.fda.gov Language: English Molecular biology Polymerase chain reaction Acute leukemia Acute promyelocytic leukemia RUNX1 Fusion gene Retinoic acid receptor alpha Real-time polymerase chain reaction CD135 Biology Transcription factors Laboratory techniques
24	Next-generation sequencing for MRD assessment in acute myeloid leukemia Michael Heuser Hematology, Hemostasis, Oncology and Stem Cell Transplantation Add to Reading List Source URL: www.fda.gov Language: English DNA sequencing Chemistry Biotechnology Polymerase chain reaction Laboratory techniques 454 Life Sciences Ion semiconductor sequencing CD135 Acute myeloid leukemia Biology Molecular biology Biochemistry
25	Wilms’ Tumour gene (WT1) as a potential MRD marker in AML David Grimwade Standardised leukaemia-specific RT-qPCR assays for Add to Reading List Source URL: www.fda.gov Language: English CEBPA WT1 Transcription factors CD135 RUNX1
26	Minimal Residual Disease as a Surrogate Endpoint in Acute Myeloid Leukemia Leukemia-associated Immunophenotypes for MRD detection in AML Adriano Venditti Add to Reading List Source URL: www.fda.gov Language: English Acute myeloid leukemia Minimal residual disease CD135 Acute leukemia Myeloid leukemia Leukemia
27	AMBIT BIOSCIENCES INITIATES FIRST PHASE 2 CLINICAL TRIAL OF AC220 IN ACUTE MYELOID LEUKEMIA Potential to Support U.S. Regulatory Filing Add to Reading List Source URL: www.forwardventures.com Language: English - Date: 2011-08-15 11:58:25 Acute myeloid leukemia Cell signaling CD135 Leukemia Quizartinib Lintuzumab Lestaurtinib Oncology Acute leukemia Myeloid leukemia
28	Microsoft Word[removed]Partnership with Ambit.doc Add to Reading List Source URL: www.forwardventures.com Language: English - Date: 2011-08-15 11:58:25 Cell signaling CD135 Acute myeloid leukemia Organic chemistry Quizartinib Tyrosine kinase Astellas Pharma Leukemia Lestaurtinib Oncology Acute leukemia Myeloid leukemia
29	Microsoft Word - ASH2009 Phase I study results - FINAL.doc Add to Reading List Source URL: www.forwardventures.com Language: English - Date: 2011-08-15 11:58:25 Acute myeloid leukemia Organic chemistry Quizartinib Chemistry Leukemia Biology Tyrosine kinase Lestaurtinib Acute leukemia Myeloid leukemia CD135
30	Frequency and Prognostic Relevance of FLT3 Mutations in Saudi Acute Myeloid Leukemia Patients Add to Reading List Source URL: www.ncbi.nlm.nih.gov Language: English Biology CD135 Myeloid leukemia Acute leukemia Acute myeloid leukemia FLT3LG Myelodysplastic syndrome Leukemia CD117 Oncology Tyrosine kinases Cell signaling